Successful re-administration of imatinib without recurrence of tumor lysis syndrome in a patient with peritoneal gastrointestinal stromal tumor.
A 69-year-old man with disseminated peritoneal gastrointestinal stromal tumor (GIST) developed tumor lysis syndrome (TLS) during imatinib therapy. Although the TLS improved after imatinib therapy was discontinued, the tumor growth accelerated. Therefore, imatinib therapy was restarted at a reduced dose, and a TLS prevention strategy was implemented that involved aggressive hydration and therapy with rasburicase and allopurinol. The tumor almost completely diminished without recurrence of TLS, and the patient has been in remission for 26 months. In the 2 previously reported cases of GIST with TLS, none of the patients survived. Our case report suggests that a TLS prevention strategy could be effective when restarting imatinib chemotherapy in sensitive solid tumors like GISTs.